Which peptides are banned in sport?

Named on the 2026 Prohibited List (27)

S0 Non-approved substances

• BPC-157Named explicitly as an example in S0.

S2.2.1 Testosterone-stimulating peptides in males

• GonadorelinNamed explicitly ("gonadotrophin-releasing hormone (GnRH, gonadorelin)"); prohibited in males.
• HCGNamed explicitly ("chorionic gonadotrophin (CG)"); prohibited in males.
• Kisspeptin-10Named ("kisspeptin and its agonist analogues"); prohibited in males.
• Kisspeptin-54Named ("kisspeptin and its agonist analogues"); prohibited in males.
• LeuprolideNamed explicitly as a GnRH agonist analogue ("leuprorelin"); prohibited in males.
• TriptorelinNamed explicitly as a GnRH agonist analogue ("triptorelin"); prohibited in males.

S2.2.2 Corticotrophins and their releasing factors

• CosyntropinNamed explicitly as "tetracosactide" (cosyntropin).

S2.2.3 Growth hormone fragments

• AOD-9604Named explicitly ("AOD-9604").
• HGH Fragment 176-191Named explicitly ("hGH 176-191").

S2.2.4 Growth hormone releasing factors

• CJC-1295Named explicitly as a GHRH analogue ("CJC-1295").
• GhrelinNamed explicitly as "lenomorelin (ghrelin)" among growth hormone secretagogues.
• GHRP-2Named explicitly ("GHRP-2 (pralmorelin)").
• GHRP-6Named explicitly ("GHRP-6").
• HexarelinNamed explicitly ("examorelin (hexarelin)").
• IpamorelinNamed explicitly ("ipamorelin").
• MK-677Named explicitly ("ibutamoren (MK-677)").
• SermorelinNamed explicitly ("sermorelin").
• TesamorelinNamed explicitly ("tesamorelin").

S2.3 Growth factors and growth factor modulators

• MGFNamed explicitly ("Mechano growth factors (MGFs)").
• TB-500Named explicitly ("Thymosin-beta4 and its derivatives e.g. TB-500").
• Thymosin beta-4Named explicitly ("Thymosin-beta4 and its derivatives").

S4.3 Agents preventing activin receptor IIB activation

• ACE-031Named explicitly ("ACE-031") as an example of a decoy activin receptor.
• Follistatin 344Named explicitly ("follistatin") as a myostatin-binding protein.

S4.4.1 Metabolic modulators (AMPK activators)

• MOTS-cNamed explicitly ("mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)").

S4.4.2 Insulins and insulin-mimetics

• Human insulinInsulins are named as a prohibited class at all times; a Therapeutic Use Exemption is required for medical use.

S5 Diuretics and masking agents

• DesmopressinNamed explicitly ("Desmopressin") as a masking agent; prohibited at all times.

Likely covered by a class rule (47)

Not named on the list, but they appear to fall under the section shown. This is our reading of the list, not a ruling by WADA or an anti-doping body.

S0 Non-approved substances

• 5-Amino-1MQNot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• AdipotideNot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• AHK-CuNot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. It is mainly sold as a cosmetic ingredient; S0 is aimed at pharmacological use.
• B7-33Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• CagrilintideNot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• CortistatinNot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• DihexaNot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. It may alternatively fall under S2.3 (growth factor modulators) because it is described as acting on the hepatocyte growth factor system.
• DSIPNot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• EfpeglenatideNot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. No approval by any regulator was found, but approvals outside the US were not exhaustively checked.
• EloralintideNot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• EpitalonNot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• FOXO4-DRINot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• GHKNot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. Plain GHK is also used as a cosmetic ingredient; S0 is aimed at pharmacological use.
• GHK-CuNot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. Topical cosmetic use may be viewed differently; S0 is aimed at pharmacological use.
• HumaninNot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• KPVNot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• LarazotideNot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• LL-37Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• Melanotan IINot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• N-Acetyl SelankNot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• NA-Semax AmidateNot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• Nesfatin-1Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• Neuropeptide YNot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• NisotirostideNot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• Orexin-ANot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• P21Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• PACAP-38Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• PE-22-28Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• PemvidutideNot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• Peptide bioregulators (Khavinson peptides)Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. Individual products vary; some short peptides in this group are reported to be registered as medicines in Russia (not verified here), which would take those specific products outside S0.
• Peptide YYNot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• PinealonNot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• PNC-27Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• PTD-DBMNot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• RetatrutideNot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• SLU-PP-332Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. Not named under S4.4 metabolic modulators (which lists AMPK activators, PPAR-delta and Rev-erb agonists).
• SurvodutideNot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• ThymulinNot named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.
• TP-508Not named. As an unapproved substance it is likely covered by S0 (prohibited at all times) unless another section applies; its reported effects on blood-vessel growth and tissue repair could also bring it under S2.3 growth factor modulators.
• UBT251Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered.

S2.1.5 Innate repair receptor agonists

• ARA-290Not named, but cibinetide is an innate repair receptor agonist, a class prohibited under S2.1.5 (likely covered).

S2.2.4 Growth hormone releasing factors

• Modified GRF 1-29Not named under this name, but S2.2.4 prohibits GHRH and its analogues (e.g., CJC-1295, sermorelin); likely covered.

S2.3 Growth factors and growth factor modulators

• IGF-1 DESNot named, but S2.3 prohibits "IGF-1 and its analogues" (likely covered).
• IGF-1 LR3Not named, but S2.3 prohibits "IGF-1 and its analogues" (likely covered).
• PEG-MGFS2.3 names "Mechano growth factors (MGFs)"; the pegylated form is likely covered.

S5 Diuretics and masking agents

• TerlipressinNot named. S5 names desmopressin and covers "other substances with a similar chemical structure or similar biological effect(s)", with an explicit exception only for dental felypressin, so vasopressin analogues are likely covered.
• VasopressinNot named. S5 names desmopressin and covers substances with similar structure or effect, with an exception only for dental felypressin, so vasopressin is likely covered.

Not on the 2026 Prohibited List (43)

Mostly approved prescription medicines. Some, such as semaglutide, are on WADA’s Monitoring Program, which tracks use without banning it.

• Abaloparatide
• Afamelanotide
• Argireline
• Bivalirudin
• Bremelanotide
• Calcitonin salmon
• Cerebrolysin
• Degarelix
• Dulaglutide
• Elamipretide
• Enfuvirtide
• Enlicitide
• Exenatide
• Glucagon
• Glutathione
• L-Carnosine
• Lanreotide
• Linaclotide
• Liraglutide
• Lixisenatide
• Matrixyl
• Mazdutide
• NAD+
• Octreotide
• Oxytocin
• Pasireotide
• Plecanatide
• Pramlintide
• Selank
• Semaglutide
• Semax
• Setmelanotide
• SNAP-8
• Teduglutide
• Teriparatide
• Thymalin
• Thymopentin
• Thymosin alpha-1
• Tirzepatide
• TRH (thyrotropin-releasing hormone)
• VIP
• Vosoritide
• Ziconotide

Sources

• WADA 2026 Prohibited List (PDF)
• WADA 2026 Monitoring Program (PDF)

Education only. PepsRadar gives no dosing or usage information. Athletes should confirm any substance with their anti-doping organization.